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Abstract 
Purpose: To investigate the effect of lyoprotectants on the physical and storage stability of lyophilised 
bovine serum albumin-loaded chitosan/dextran sulphate (BSA-loaded CS/DS) nanoparticles.  
Methods: BSA-loaded CS/DS nanoparticles were prepared by ionic-gelation technique. The 
nanoparticles were harvested by ultra-centrifugation and then various lyoprotectants at different 
concentrations were added to the nanoparticles prior to lyophilisation at – 40 oC for 24 h. Particle size 
and distribution as well as zeta potential of the nanoparticles were measured by dynamic light scattering 
method. Entrapment efficiency and BSA retained in the nanoparticles matrices were determined 
spectrophotometrically at λmax of 595 nm.   
Results: The results indicate that 0.5 %w/v trehalose was the most effective lyoprotectant and it 
essentially maintained the particle size of lyophilised BSA-loaded CS/DS nanoparticles which changed 
slightly from 188 ± 11 nm to 174 ± 14 nm during lyophilisation. Mannitol was also as effective as 
trehalose at 0.1 and 1.0 % w/v in stabilising the nanoparticles.  The particle size of lyophilized 
nanoparticles increased moderately from 188 ± 11 nm to 234 ± 12 nm and 287 ± 18 nm at 0.1 and 1.0 
% w/v, respectively. In contrast, the other lyoprotectants (inulin and histidine) did not show stabilizing 
effects. Moreover, trehalose also  reduced the degree of particle aggregation from 329 ± 16 to 836 ± 21 
nm upon storage for 24 h as compared to CS/DS nanoparticles without trehalose; from 438 ± 14 to 
1298 ± 18 (p < 0.05). The rate of BSA leakage from the nanoparticles containing trehalose was reduced 
from 92 to 42 % over a 11-day storage period compared with 99 to 0 % for CS/DS nanoparticles without 
trehalose. 
Conclusion: Trehalose (0.5 % w/v) is a promising lyoprotectant for storage stabilisation of BSA-loaded 
CS/DS nanoparticles.  
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For the past two decades, a great deal of efforts 
has been focused on the fabrication of drug 
delivery vehicles including liposome, mixed 
micelles, microspheres, and polymeric 
nanoparticles [1,2]. Among all these, polymeric 
nanoparticles are more striking delivery system 
due to its ability to pass through the smaller 
capillaries and tissue gaps to arrive at target 
sites as well as its controlled release properties 
[2,3]. Among various materials investigated for 
preparing polymeric nanoparticles; chitosan 
(CS), a natural bio-polymer derived from chitin 
deacetylation [4,5] has attained considerable 
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attention due to its excellent biocompatibility, 
biodegradability and antibacterial properties [6]. 
Recently, polymeric nanoparticles have been 
prepared from chitosan and dextran sulphate 
(DS) with higher stability and mechanical 
strength as compared to chitosan-
tripolyphosphate (CS/TPP) nanoparticles [7,8]. 
However, their clinical applications are often 
limited by the thermodynamic instability of their 
colloidal dispersion for prolonged time periods. 
This physical instability is mostly induced by the 
aggregation and precipitation of the particles in 
the formulation [9] and could be further 
aggravated by fluctuations in temperature. To 
alleviate these problems and to improve the 
storage stability of CS/DS nanoparticles, 
lyophilisation has been used [9]. However, the 
physical stresses encountered during the 
lyophilisation process further lead to the fusion of 
particles induced by dehydration–rehydration 
processes. To overcome this problem and to 
promote the physical stability of particles, 
carbohydrates lyoprotectants have been 
employed [10,11]. However, phase separation or 
crystallisation of lyoprotectants, either during the 
lyophilisation process or subsequent storage 
may adversely influence the stability of 
nanoparticles [12,13]. Thus, the aim of the 
present study was to evaluate the effects of 
lyophilisation process and the lyoprotective 
agents on the physical characteristics of CS/DS 
nanoparticles in order to improve their physical 






Low molecular weight chitosan (deacetylation 
degree (DD) 75 – 85 %, M. Wt 70 kDa), glacial 
acetic acid, dextran sulphate (DS), bovine serum 
albumin (BSA) (mol wt, 46 kDa), Bradford 
reagent and phosphate buffer saline (PBS) were 
purchased from Sigma–Aldrich, USA. Other 
chemicals such as mannitol and inulin were 
obtained from Chicory while histidine and 
trehalose were obtained from Sigma–Aldrich, 
Malaysia.  
 
Preparation of CS/DS nanoparticles  
 
CS/DS nanoparticles were prepared via ionic-
gelation method, previously developed by Calvo 
et al [14]. Accordingly, 100 mg of CS was 
dissolved in 100 ml of 2 % v/v glacial acetic acid 
to produce 0.1 % w/v CS solution. A 
concentration of 0.1 % w/v of DS was prepared 
by dissolving 100 mg of DS in 100 ml of distilled 
water. CS/DS nanoparticles were simultaneously 
prepared by adding 4 ml of DS solution dropwise 
into the 10 ml 0.1 % w/v CS solution under a 
constant magnetic stirring at 700 rpm for 30 min. 
Thereafter, CS/DS nanoparticles were harvested 
by ultra-centrifugation (25000 rpm) using Optima 
L-100 XP Ultracentrifuge with a rotor NV 70.1 Ti 
(Beckman-Coulter, USA) at 10 oC for 15 min. 
 
Preparation of BSA-loaded CS/DS 
nanoparticles 
 
For the association of BSA with CS/DS 
nanoparticles, BSA was dissolved in PBS 
solution to produce 0.1%w/v concentration. 
Then, BSA solution was mixed with 0.1 % w/v 
CS solution and incubated for 30 min at room 
temperature. Afterward, 4 ml of 0.1 % w/v DS 
solution was added dropwise into the mixture 
under a constant magnetic stirring at 700 rpm for 
30 min, to produce BSA-loaded CS/DS 
nanoparticles. The resultant nanoparticles were 
harvested by ultra-centrifugation at 25000 rpm at 
10 oC for 15 min [15]. 
 
Lyophilisation of blank and BSA-loaded 
CS/DS nanoparticles  
 
The resultant CS/DS nanoparticles pellets were 
resuspended in 5 ml of distilled water containing 
selected lyoprotectants (trehalose, mannitol, 
inulin or histidine) at different concentrations (0.1, 
0.5 or 1.0 % w/v). The resulting suspensions 
were frozen at – 20 oC overnight prior to the 
lyophilisation process at a pressure of 1.3 x 106 
atm, at – 40 oC for 24 h.  
 
Determination of particle size, polydispersity 
index (PDI) and zeta potential 
 
Mean particle size, PDI and zeta potential of 
BSA-loaded CS/DS nanoparticles with and 
without the addition of lyoprotectants were 
measured by ZS-90 Zetasizer® (Malvern 
Instruments, UK). Samples were either re-
dispersed in distilled water or PBS (pH 7.4) prior 
to the measurements. All measurements were 
performed in triplicate at 25 oC with a detection 
angle of 90o. Results were reported as mean ± 
standard deviation. 
 
Determination of entrapment efficiency (EE) 
 
To estimate EE, the supernatant recovered after 
ultra-centrifugation was decanted and the BSA 
content was analysed using “Bradford protein 
assay” as per manufacturer’s instructions. The 
absorbance of the sample was recorded using 
UV/Vis-spectrophotometer (UV-1601, Shimadzu, 
Japan) at λmax of 595 nm. EE of BSA was 
calculated using Eq 1 [16].  
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EE (%) = (Wt–Wf/Wt) × 100 ………………… (1) 
 
where, W t is the total initial amount of BSA and 
Wf is the amount of free BSA into the 
supernatant recovered after ultra-centrifugation. 
 
Stability studies of BSA-loaded CS/DS 
nanoparticles  
 
Lyophilised BSA-loaded CS/DS nanoparticles 
were stored in desiccators for 32-days at room 
temperature (25 ± 2 oC). The sample (100 mg) 
was re-hydrated and suspended in 100 mL of 
PBS (pH 7.4, 0.01 M). The percentage of BSA 
retained in the matrix of BSA-loaded CS/DS 
nanoparticles and their particle size were 
determined at the beginning and pre-determined 





The dry samples of BSA-loaded CS/DS 
nanoparticles (100 mg) with or without trehalose 
were immersed in 100 mL of PBS (pH 7.4)  at 
room temperature (25 ± 2 oC) for 32-days. The 
swollen samples were then collected at various 
day-intervals (0, 2, 4, 8, 11, 18, 22, 24, 25 and 
32) by ultra-filtration. The swollen samples were 
then blotted with filter paper to remove excess 
adsorbed water from the surface of BSA-loaded 
CS/DS nanoparticles and weighed immediately. 
Swelling ratio (S) was calculated by using Eq 2 
[17] 
 
S (%) = (Ws–Wd/Wd) × 100 …………. (2) 
 
where, Ws and Wd are the weights of swollen and 




All the data were presented as mean ± standard 
deviation (SD), and analysed with either paired t-
test or independent t-test using SPSS 19.0. For 
independent t-test and paired t-test , p < 0.05 
was indicative of significant difference between 









The mean particle size of blank CS/DS 
nanoparticles (without BSA) as well as the BSA-
loaded CS/DS nanoparticles was significantly 
influenced (p < 0.05, unpaired t-test) by the 
process of ultra-centrifugation. Resulting data 
suggested that the mean particle size of blank 
CS/DS nanoparticles decreased from 303 ± 16 
nm to 193 ± 8 nm, after ultra-centrifugation. 
Similarly, the particle size of BSA-loaded CS/DS 
nanoparticles was also reduced from 301 ± 14 
nm to 206 ± 6 nm. 
 
Zeta potential and polydispersity index (PDI) 
 
The data obtained depict that the zeta potential 
of blank CS/DS nanoparticles was significantly 
decreased (p< 0.05) from +67 ± 4 mV to +31 ± 
0.6 mV after ultra-centrifugation. The average 
surface charge of BSA-loaded CS/DS 
nanoparticles was also remarkably decreased 
(p< 0.05) from +69 ± 4 mV to +25 ± 3 mV. 
Furthermore, the mean value of PDI for the blank 
and BSA-loaded CS/DS nanoparticles was 
considerably reduced from 0.318 ± 0.001 and 
0.335 ± 0.02 to 0.149 ± 0.006 and 0.162 ± 0.006 
respectively, after ultra-centrifugation which 
indicate that their particle size was narrowly 
distributed.  
 
Effects of types and concentrations of 
lyoprotectants  
 
Fig 1 (A) represents the various modulations of 
the particle size of BSA-loaded CS/DS 
nanoparticles containing different types and 
concentrations of lyoprotectants before and after 
lyophilisation process. Before lyophilization, the 
blank CS/DS nanoparticles without lyoprotectant 
(control) showed significant increase (p < 0.05) in 
the particle size from 193 ± 8 to 351 ± 13 nm 
after lyophilisation. Similar to that, the zeta 
potential of the control had shown a considerable 
decrease (p < 0.05) from +31 ± 0.6 to +23 ± 3.5 
mV after lyophilisation process as depicted by 
Fig 1(B). The PDI value of the control group 
showed significant increase by 3.2-fold to 0.49 ± 
0.01. On the other hand, the BSA-loaded CS/DS 
nanoparticles had also shown a significant (p < 
0.05) variation in the particle size from 206 ± 6 to 
363 ± 18 nm and in the zeta potential from +25 ± 
3 to 19 ± 2 mV after lyophilization. To circumvent 
this problem, different types of lyoprotectants 
were investigated as shown in Fig 1. It was found 
that the particle size of CS/DS nanoparticles 
containing 0.5 % w/v trehalose remained 
essentially unchanged after lyophilisation. In-
addition, the mannitol was as effective as 
trehalose in maintaining the particle size of 
CS/DS nanoparticles at 0.1 and 1.0 % w/v (p > 
0.05). However, at a concentration of 0.5 %w/v, 
mannitol was less effective than trehalose. In 
contrast, other lyoprotectants (inulin and 
histidine) were clearly less effective in this 
regard, as shown in Fig. 1A. Furthermore, the 
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surface charge of CS/DS nanoparticles was least 
affected by lyophilization when trehalose was 
used as stabilizer compared to the other 
lyoprotectants as shown in Fig 1(B). The results 
suggested that trehalose was very effective at 
0.1 and 0.5 % w/v concentration at maintaining 
the zeta potential of CS/DS nanoparticles. On the 
other hand, the other lyoprotectants did not 
prevent the adverse effects of lyophilization (Fig 
1B). Thus, the ,trehalose (0.5 % w/v) was the 
most effective agent in preserving the physical 
characteristics of CS/DS nanoparticles, and 




Fig 1: Effects of different types and concentrations of 
lyoprotectants on (A) particle size and (B) zeta 
potential of CS/DS nanoparticles. *CS/DS 
nanoparticles were rehydrated and suspended in 
distilled water, n=3. 
 
Storage stability of BSA-loaded CS/DS 
nanoparticles  
 
It was addressed by the previous experiments 
that trehalose was the most efficient to stabilize 
lyophilized CS/DS nanoparticles. Taken together, 
the stabilization effect of trehalose on CS/DS 
nanoparticles was also accessed upon storage. 
Three parameters were measured: 1) mean 
particle size, 2) zeta potential 3) percent of BSA 
retained in the matrices of CS/DS nanoparticles. 
For this experiment, the EE of BSA-loaded 
CS/DS nanoparticles containing 0.5 %w/v 
trehalose was 92 % prior to the lyophilisation 
process. On the other hand, EE for BSA-loaded 
CS/DS nanoparticles without the addition of 
trehalose was 98 % and was used as a control.  
 
Particle size and zeta potential of CS/DS 
nanoparticles 
 
Results highlighted in Fig 2 suggested that 
trehalose could protect the nanoparticles from 
forming aggregates induced by lyophilisation 
process. The mean particle size of control 
sample (lyophilised nanoparticles without 
trehalose 0.5 %w/v) was significantly increased 
from 438 ± 14 to 1298 ± 18 (p < 0.05, paired t-
test) from day-0 to day-32, which indicated 
extensive particle aggregation as expressed by 
Fig 2. In contrast to that, the average particle 
size of lyophilised BSA-loaded CS/DS 
nanoparticles containing trehalose (0.5 %w/v) 
increased gradually from 329 ± 5 to 836 ± 6 (p < 
0.05, paired t-test) from day-0 to day-32.  
 
 
Fig 2: Effect of storage of BSA-loaded CS/DS 
nanoparticles (CS 0.1%w/v, DS 0.1%w/v, BSA 
0.1%w/v) with (□) and without (◊) trehalose 0.5 %w/v 
on particle size. The nanoparticles were re-hydrated 
and suspended in PBS (pH 7.4, n = 3) 
 
Moreover, Table 1 shows the modulation of zeta 
potential of BSA-loaded CS/DS nanoparticles 
with and without trehalose 0.5 % w/v. The zeta 
potential of nanoparticles with trehalose 0.5 % 
w/v was more negatively charged than CS/DS 
nanoparticles without trehalose -during storage. 
 
BSA retention in CS/DS nanoparticles  
 
The results presented in Fig 3 demonstrate that 
the leakage of BSA from BSA-loaded CS/DS 
nanoparticles into the suspending medium 
progressed slowly in the presence of trehalose  
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Table 1: Effect of trehalose (0.5 %w/v) on zeta potential and PDI of BSA-loaded CS/DS nanoparticles 
upon storage (mean ± SD, n = 3). 
 
BSA-loaded CS/DS NPs without trehalose 
(0.5 % w/v) 
BSA-loaded CS/DS NPs with trehalose (0.5 % 
w/v) Storage 
Period 
(day) PDI Surface charge (mV) PDI Surface charge (mV) 
0 0.50 ± 0.06 -8.00 ± 0.30 0.34 ± 0.01 -15.00 ± 0.82 
1 0.61 ± 0.01  -7.00 ± 0.51 0.37 ± 0.01 -11.00 ± 0.15 
2 0.58 ± 0.12  -8.00 ± 0.28 0.54 ± 0.05 -11.00 ± 0.91 
3 0.59 ± 0.01 -12.00 ± 1.84 0.61 ± 0.02 -16.00 ± 0.55 
4 0.58 ± 0.12 -10.00 ± 1.13 0.45 ± 0.01          -13.00 ± 0.41 
11   0.49  ± 0.004  -9.00 ± 0.02 0.56 ± 0.02 -12.00 ± 0.46 
18 0.71 ± 0.11  -7.00 ± 1.04 0.39 ± 0.01 -16.00 ± 0.15 
25 0.59 ± 0.01  -7.00 ± 0.55 0.49 ± 0.01 -12.00 ± 1.13 
32   0.60 ± 0.004  -4.00 ± 0.77 0.23 ± 0.00           -9.00 ± 0.80 
 
 
Fig 3: Effect of storage of BSA-loaded CS/DS nanoparticles (CS 0.1 %w/v, DS 0.1 %w/v, BSA 0.1 % w/v) with or 
without trehalose 0.5 %w/v on the percent of BSA retained in the matrix of CS/DS nanoparticles. *CS/DS 
nanoparticles were rehydrated and suspended in PBS (pH 7.4, n = 3) 
 
(0.5 %w/v). The resulting data revealed that 
the percent of BSA retained was reduced from 
92 % to 42 % from Day-0 to 11. The percent of 
drug retained showed an abrupt fall to 14 % at 
Day-18. Furthermore, the percent of BSA 
retained dropped to zero at day-25 of storage. 
In contrast to that, BSA rapidly leaked from the 
CS/DS nanoparticles without trehalose from 
99 % to 8 % from day-0 to day-8. Thus, the 
CS/DS nanoparticles without trehalose were 
observed to be completely lost their active 




In order to investigate the effects of storage on 
the swelling characteristics of BSA-loaded 
CS/DS nanoparticles, a series of experiments 
were carried out from day-0 to 32. Fig 4 
reveals that the swelling ratios of BSA-loaded 
CS/DS nanoparticles without trehalose was 
observed to be significantly increased (p< 
0.05, student t-test) from 26 % to 81 % from 
day-2 to 32. In addition to that, the swelling 
ratio of CS/DS nanoparticles containing 
trehalose 0.5% w/v was significantly lower (p < 
0.05, student t-test) than the ones without 
trehalose as shown by Fig 4. 
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Fig 4: Effect of trehalose 0.5 %w/v on the swelling ratio of BSA-loaded CS/DS nanoparticles upon storage. 




The data obtained from the study suggested that 
ultra-centrifugation process may adversely 
affects the physical characteristics of CS/DS 
nanoparticles, which were also corroborated with 
the previous findings reported by Katas et al [18]. 
This phenomenon could be attributed to the 
reason that smaller particles may adsorb on the 
surface of larger particles via partial physical 
interactions to form agglomerates. However, 
during ultra-centrifugation process, the surface 
adsorbed particles could be washed away from 
the larger particles due to high centrifugation 
speed [18]. Similarly, the average zeta potential 
and PDI of nanoparticles was also observed to 
be affected by centrifugation process. 
 
Fig 1 illustrate that trehalose was more efficient 
in preventing the drastic modification of the 
physical characteristics of lyophilised CS/DS 
nanoparticles. The particle size of lyophilised 
nanoparticles with trehalose was the least 
affected by the process of lyophilisation. On the 
other hand, other lyoprotectants such as 
mannitol, inulin and histidine were less effective 
in preventing particle aggregation induced by 
lyophilisation process. Moreover, the zeta 
potential of CS/DS nanoparticles containing 
inulin or histidine was also observed to be 
reduced significantly (p < 0.05, paired t-test). The 
low surface charge value of CS/DS nanoparticles 
in the presence of inulin or histidine contributed 
to the relatively lesser repulsive forces among 
individual particles and therefore, they tend to 
form aggregates. This was expected to be due to 
the crystallisation of both inulin and histidine 
during lyophilisation which was also in 
accordance with the theories proposed by 
Mohammed et al and Andre et al [12,19]. They 
reported that inulin exists in two crystalline forms 
which are semi-hydrated and hydrated and thus, 
the particles tend to form agglomerates. 
 
Moreover, PDI is crucially important to be 
evaluated as it indicates the conservation of 
particle size distribution. Results depicted that 
the PDI values of CS/DS nanoparticles with the 
addition of inulin and histidine were significantly 
increased (p< 0.05, paired t-test) compared to 
the controls (nanoparticles without lyoprotectant 
and before lyophilisation process). Based on 
these results, it was elucidated that all other 
lyoprotectants except trehalose were shown to 
be less effective in protecting CS/DS 
nanoparticles from forming aggregates caused 
by the dehydration and other physical stresses 
during lyophilisation process. These results were 
also corroborated with other findings reported in 
previous studies [11-13].  
 
A significant increase in the particle size of 
nanoparticles was also observed with all other 
concentrations of trehalose (0.1 and 1.0 %w/v). 
This finding therefore suggested that the other 
concentrations could not sufficiently protect the 
lyophilised nanoparticles as achieved by %w/v 
trehalose 0.5. This was thought to be caused by 
the destabilisation of the nanoparticles due to the 
fact that trehalose might have reached its limit of 
destabilisation [9-11].  
 
Trehalose 0.5 % w/v was found to be able to 
retain the particle size of lyophilised BSA-loaded 
CS/DS nanoparticles up to day-4 of storage (Fig 
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2). A significant increase in their particle size was 
only observed from day-11 of storage. The pre-
treatment of CS/DS nanoparticles with trehalose 
would not only preserve the particle size 
efficiently, but also minimise the drug leakage 
from nanoparticles matrices [15,19]. The 
desorption of loosely bound BSA molecules from 
the surface of the CS/DS nanoparticles was 
reported to be responsible for the higher rate and 
extent of BSA leakage from nanoparticles 
matrices without trehalose when they were 
suspended in a medium. In contrast to that, a 
comparatively lower rate and extent of BSA 
leakage from the BSA-loaded CS/DS 
nanoparticles in the presence of trehalose could 
be due to the formation of an extra protective 
barrier on the nanoparticles surfaces which could 
slow down the rapid leakage of BSA as shown in 
Fig 3. 
 
CS/DS nanoparticles without trehalose had a 
higher swelling percentage as compared to the 
nanoparticles with trehalose 0.5 % w/v. It was 
expected as the CS/DS nanoparticles without 
trehalose were directly exposed to the external 
environment (PBS, pH 7.4), which caused the –
NH3+ groups on the contour of CS to change into 
neutral –NH2 group. As a result, the electrostatic 
interactions between CS and DS became 
extensively weakened which favours the swelling 
of CS/DS nanoparticles. However, the addition of 
trehalose into the formulation had allowed an 
extra lyoprotective layer to be formed on the 
surface of nanoparticles and protect them from 
external environment (PBS, pH 7.4). This could 
therefore cause the cross-linking efficiency to be 
remained stable which subsequently inhibited the 




In this present research, the successful loading 
of BSA into the CS/DS nanoparticles was 
achieved via ionic-gelation method. It was 
demonstrated that the physical characteristics 
(particle size, PDI and zeta potential) of BSA-
loaded CS/DS nanoparticles were significantly 
influenced by the process of lyophilisation. To 
circumvent this physical instability induced by 
lyophilisation, various lyoprotective agents have 
been investigated. It was observed that 0.5 % 
w/v trehalose was more effective to physically 
stabilise the lyophilised BSA-loaded CS/DS 
nanoparticles. Data obtained also suggested that 
0.5 % w/v trehalose could be used to reduce the 
rate and extent of BSA leakage upon storage. 
These findings therefore suggest that trehalose 
could be used to provide physical protection 
during lyophilisation and to improve the storage 
stability of BSA-loaded CS/DS nanoparticles. 
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